Specification
Description
AZD-5099 is a DNA gyrase modulator potentially for the treatment of bacterial infection.
Synonyms
AZD-5099; AZD 5099; AZD5099
IUPAC Name
2-((3S,4R)-4-(3,4-dichloro-5-methyl-1H-pyrrole-2-carboxamido)-3-methoxypiperidin-1-yl)-4-(((S)-1-methoxypropan-2-yl)carbamoyl)thiazole-5-carboxylic acid
Canonical SMILES
O=C(C1=C(C(N[C@@H](C)COC)=O)N=C(N2C[C@H](OC)[C@H](NC(C3=C(Cl)C(Cl)=C(C)N3)=O)CC2)S1)O
InChI
InChI=1S/C21H27Cl2N5O6S/c1-9(8-33-3)24-19(30)16-17(20(31)32)35-21(27-16)28-6-5-11(12(7-28)34-4)26-18(29)15-14(23)13(22)10(2)25-15/h9,11-12,25H,5-8H2,1-4H3,(H,24,30)(H,26,29)(H,31,32)/t9-,11+,12-/m0/s1
InChI Key
KGZHRAVDXGQUQM-WCQGTBRESA-N
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Storage
Dry, dark and at 0-4 °C for short term (days to weeks) or -20 °C for long term (months to years).
Biological Target
AZD5099, an antibacterial agent, is a potent and selective bacterial topoisomerase II inhibitor.
Drug Formulation
This drug may be formulated in DMSO
Elemental Analysis
C, 45.99; H, 4.96; Cl, 12.93; N, 12.77; O, 17.50; S, 5.85
HS Tariff Code
2934.99.9001
In Vivo Activity
AZD5099 (compound 63) is an antibacterial agent that entered phase 1 clinical trials targeting infections caused by Gram-positive and fastidious Gram-negative bacteria. Compound 63 showed notable efficacy in a mouse neutropenic Staphylococcus aureus infection model. Resistance frequency versus the drug was low, and reports of clinical resistance due to alteration of the target are few.
Reference: J Med Chem. 2014 Jul 24;57(14):6060-82. https://pubmed.ncbi.nlm.nih.gov/24959892/
Shipping
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Stock Solution Storage
0-4 °C for short term (days to weeks), or -20 °C for long term (months).